Propelling the Understanding and Treatment of Disease

Broad Institute of MIT and Harvard was launched in 2004 to empower this generation of creative scientists to transform medicine. The Broad Institute seeks to describe the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods and data openly to the entire scientific community. Founded by MIT, Harvard, Harvard-affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide.

Translating Curiosity-Driven Academic Research into Drug Discovery Projects

The Center for the Development of Therapeutics (CDoT) at the Broad Institute is an organization of professional drug discovery scientists whose mission is to translate the biological insights developed at the Broad into therapeutics. CDoT is deeply embedded within the Broad Institute. In its structure, capabilities and leadership experience, CDoT closely resembles the drug discovery group of a pharma/biotech.

Investors in Life Science

Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding and investment company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Foundation’s assets. Novo Holdings is recognized as a world-leading life science investor with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Within growth equity, Novo Holdings focuses on providing expansion capital to innovative life science companies with a strong revenue growth profile. Novo Holdings also manages a broad portfolio of diversified financial assets. Given Novo Holdings’ evergreen funding structure, multiple investment strategies and global reach, Novo Holdings is uniquely positioned to invest in and support life science companies from inception through commercialization.

Life Science Venture Investing in the US and Europe

Novo Ventures is one of several investment teams employed by Novo affiliates that supports the investment activities of Novo Holdings, one of the world’s largest life science focused investment companies. Novo Ventures aims to facilitate the investment of approximately $500 million annually in private and public life science opportunities in the US, Europe and Asia.  With a presence in Copenhagen, London, San Francisco and Boston, Novo Ventures is well positioned in the major global life science hubs. Since 2014, the Novo Ventures team has facilitated the investment of ~$1.9B USD in 106 companies, and successfully exited 68, through both IPOs and divestitures.


*Novo Ventures (US) Inc. is a separate legal entity that provides certain consultancy services to Novo Holdings A/S, mainly within the areas of identifying, analyzing and negotiating various investment opportunities among life science and biotech companies and monitoring such investments.

Contact The Greenhouse

The Novo Broad Greenhouse

Broad Institute of MIT and Harvard

415 Main St. Cambridge, MA 02142

Email Us